Reassessing recombinant human activated protein C for sepsis: time for a new randomized controlled trial.
Reassessing recombinant human activated protein C for sepsis: time for a new randomized controlled trial.
复制标题
重新评估重组人活化蛋白 C 治疗脓毒症:是时候进行新的随机对照试验了。
DOI:
10.1097/01.ccm.0000183002.26587.ff
复制
发表时间:
2005
影响因子:
8.8
通讯作者:
Natanson,Charles
中科院分区:
文献类型:
--
作者:
Eichacker,PeterQ;Danner,RobertL;Suffredini,AnthonyF;Cui,Xizhong;Natanson,Charles
It is associated with a mortality rate of 30%(1), and the quality of life of survivors is reduced after discharge (2). We are still lacking effective treatment, possibly in part because our current ARDS definition leads to the enrollment of patients in clinical trials who differ with respect to severity, etiology (eg, primary vs. secondary), and/or mode of presentation (eg, diffuse vs. localized ARDS) of lung injury (3). It is likely easier to find an effective treatment for a well-defined entity (eg, pneumonia) than for the number of loosely related entities currently grouped under the ARDS “umbrella.” The treatment of patients with ARDS currently consists essentially of ventilatory support with positive pressure. Although the key objectives of mechanical ventilation are widely agreed on—restoration/maintenance of adequate gas exchange and implementation of a lung-protective strategy to buy time for lung repair—the best way to achieve this is controversial, particularly in difficult patients. In the presence of refractory hypoxemia, for instance, different rescue strategies have been proposed including inhaled vasodilator (nitric oxide or prostacyclin), a high level of positive end-expiratory pressure (PEEP), recruitment maneuvers, prone positioning (PP), high-frequency oscillatory ventilation (HFOV), or extracorporeal membrane oxygenation. None of these strategies has been proven to improve outcome, and the initial enthusiasm for these techniques has almost invariably been followed by disappointment.Experimental works have established (4) that a) positive pressure ventilation can induce endothelial and epithelial dysfunctional and structural injury; b) the magnitude of the tidal volume relative to the size of the lung that must accommodate the latter is a key determinant of alveolar overdistension and injury (volutrauma)(5); and c) an adequate level of PEEP is needed to protect the lungs from cyclic airway opening and collapse (atelectrauma) and/or also from the strain and stress associated with large tidal excursion (5, 6). We are, however, still debating how to best protect the lungs from ventilator-induced lung injury (VILI). Although the need to avoid excessive tidal volume is now clinically confirmed (7), a recent large multiple-center study failed to confirm the protective effect of PEEP (8). This may have been the combined consequence of enrollment of patients with different forms of lung injury and variable responses to the specific PEEP titration protocol used in this study, as recently pointed out (9). PP and HFOV have been proposed as alternative strategies to conventional mechanical ventilation and PEEP, particularly in patients doing poorly, given their dual potential to improve gas exchange and prevent the development of VILI. Overall, 70% of patients with acute lung injury/ARDS experience improved PaO2/FIO2 ratio when turned prone (10). In addition, PP appears to be particularly advantageous over PEEP in the localized forms of ARDS (11). HFVO’s ability to improve blood gas in selected adults with difficult to treat ARDS has been reported in uncontrolled series (12). In a recent randomized trial, however, no significant difference in mortality rate and only a transient improvement in gas exchange were observed (13). As reported in the prone trials (10, 14), improved gas exchange does not necessarily translate into better outcome. Indeed, as learned from the ARDSnet trial (7), how a given ventilatory strategy modulates lung stress and injury is a more important determinant
登录
查看更多内容
影响因子:
3.3
作者:
LEMEN, R;BENSON, M;JONES, JG
通讯作者:
JONES, JG
影响因子:
7.3
作者:
FLOWER, RJ;HARVEY, EA;KINGSTON, WP
通讯作者:
KINGSTON, WP
DOI:
--
发表时间:
1971
期刊:
Journal of Allergy
影响因子:
--
作者:
Y. Takino;K. Sugahara;I. Horino
通讯作者:
I. Horino
影响因子:
6.4
作者:
G. Holme;H. Piechuta
通讯作者:
H. Piechuta
DOI:
10.1152/jappl.1983.55.4.1232
发表时间:
1983
期刊:
Journal of applied physiology: respiratory, environmental and exercise physiology
影响因子:
--
作者:
Holtzman,MJ;Fabbri,LM;Skoogh,BE;O'Byrne,PM;Walters,EH;Aizawa,H;Nadel,JA
通讯作者:
Nadel,JA